A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration

Table 4 Category 3 AMD cases undergoing genetic testing: baseline vision in neovascular AMD eyes in clinical practice integrated with MARINA trial presenting percentages

Model	n	% of baseline patients [18, 20]^a	Mean vision	% with initial vision 20/40–20/80	% with initial vision ≤20/160
A. 1st eye	50	53.6	20/182	18	78.0
B. 2nd eye	98	46.4	20/84	37	62.2
Both eyes (A × B)	148	100.0	20/136	6.7	48.5
C. Sensitivity of genetic testing	148	90	NA	A × B × C = 6.0 %	A × B × C = 43.7 %

AMD age-related macular degeneration, NA not applicable
^aMARINA (Minimally classic/occult trial of the Anti-VEGF antibody Ranibizumab In the treatment of Neovascular AMD) clinical trial [18, 20]

ISSN: 2056-9920